Meeting ReportPoster - PhysicianPharm
Comparing clinical evaluation of PET segmentation methods with reference-based metrics and no-gold-standard evaluation technique
Yansong Zhu, Fereshteh Yousefirizi, Ziping Liu, Ivan Klyuzhin, Arman Rahmim and Abhinav Jha
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1430;
Yansong Zhu
2Johns Hopkins University Baltimore MD United States
1BC Cancer Research Institute Vancouver BC Canada
3BC Cancer Research Institute Vancouver BC Canada
Fereshteh Yousefirizi
1BC Cancer Research Institute Vancouver BC Canada
3BC Cancer Research Institute Vancouver BC Canada
Ziping Liu
4Washington University in St. Louis St. Louis MO United States
Ivan Klyuzhin
1BC Cancer Research Institute Vancouver BC Canada
3BC Cancer Research Institute Vancouver BC Canada
Arman Rahmim
1BC Cancer Research Institute Vancouver BC Canada
3BC Cancer Research Institute Vancouver BC Canada
Abhinav Jha
4Washington University in St. Louis St. Louis MO United States

Article Figures & Data
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
Comparing clinical evaluation of PET segmentation methods with reference-based metrics and no-gold-standard evaluation technique
Yansong Zhu, Fereshteh Yousefirizi, Ziping Liu, Ivan Klyuzhin, Arman Rahmim, Abhinav Jha
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1430;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
- Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression
- Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data
- PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
- Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy
- 68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer
- The Association Between [68Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy